Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972620 | 0.98 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL16551785 | 0.88 | MEN1 (0.33) | HSD17B10SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9932019 | 0.83 | PEPD (0.31) | MEN1KMT2A | |
| SCHEMBL9931550 | 0.83 | PEPD (0.31) | MEN1KMT2A | |
| SCHEMBL9931548 | 0.83 | PEPD (0.31) | MEN1KMT2A | |
| SCHEMBL9931549 | 0.83 | PEPD (0.31) | MEN1KMT2A | |
| SCHEMBL8917960 | 0.83 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2688423 | 0.81 | ALDH1A1 (0.41) | HSD17B10ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2688427 | 0.81 | ALDH1A1 (0.41) | HSD17B10ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2688426 | 0.81 | ALDH1A1 (0.41) | HSD17B10ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2010139411-A2 | 17β-ALKYL-17α-OXY-ESTRATRIENES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | CYP19A1, HSD17B11, CYP17A1 | HSD17B10 58/4885SMN1; SMN2 3753/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.